Treatment outcome for metastatic papillary renal cell carcinoma patients
β Scribed by Ellen A. Ronnen; G. Varuni Kondagunta; Nicole Ishill; Lesley Spodek; Paul Russo; Victor Reuter; Jennifer Bacik; Robert J. Motzer
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 91 KB
- Volume
- 107
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically during the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab with interferon Ξ±, temsirolimus, and everolimus have improved clinical outcomes in randomized phase 3 trials by inhibiting the vas
## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferonβalfa as firstβline therapy in patients with metastatic clearβcell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi
## BACKGROUND. The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional F